Delivering Hope: How Endurex Pharmaceuticals Is Redefining Drug Delivery
In the fight against cancer and other hard-to-treat diseases, innovation doesn’t always mean inventing new drugs—it can mean rethinking how drugs are delivered. That’s the mission of David Lloyd, President and CEO of Endurex Pharmaceuticals, who is leading a team developing a groundbreaking peptide-directed nanoparticle delivery platform that could change how patients experience treatment.
On Industry Ignited, Lloyd sat down with Dr. Leeanne Aguilar to discuss his unlikely journey from finance to biotech, the personal story that fuels his mission, and how Endurex is applying a manufacturing mindset to scale life-saving therapies.
From Finance to Pharma
Lloyd is the first to admit he didn’t come from science. A self-described “escaped CPA,” he stepped into Endurex leadership almost by accident after working with the company on financial matters. But the timing—and his motivation—were deeply personal.
His late wife, a patient advocate, passed away from a recurrence of breast cancer in 2012. That experience as a caregiver left him determined to make a difference in cancer care. “I saw firsthand the need for better options,” he explains. “When the opportunity to lead Endurex came, I knew it was worth pursuing.”
Rethinking Chemotherapy
Traditional chemotherapy, Lloyd notes, is blunt and toxic—delivered systemically with little precision. Patients endure severe side effects, and tumors often develop resistance.
Endurex’s approach is different:
Nanoparticles as delivery boxes — Think of them as FedEx packages. Drugs are placed inside and “addressed” using peptides that act as cellular zip codes.
Targeted delivery — Instead of attacking the whole body, the nanoparticles release their cargo directly into tumor tissue.
Combination potential — Multiple therapies can be delivered in the same “box,” increasing efficacy compared to separate administration.
The result? Higher drug concentrations where they’re needed, less toxicity elsewhere, and potentially fewer long-term side effects for patients.
Partnerships and Collaboration
Endurex’s progress is fueled by partnerships with leading institutions like MD Anderson Cancer Center. These collaborations bring critical expertise, resources, and credibility.
Lloyd is clear: “We’re not inventing new drugs—we’re improving the delivery of approved ones. That means we can enhance safety, efficacy, and patient experience without starting from scratch in the regulatory process.”
Beyond Cancer: A Platform for the Future
While current efforts focus on cancer, Endurex’s platform has much broader potential:
Immunotherapies — Delivering agents that help the body’s immune system fight disease.
Gene therapies — Transporting RNA or DNA constructs to correct mutations at the source.
Vaccines — Enhancing delivery to prevent disease before it starts.
“This is the holy grail,” Lloyd says. “Not just poisoning cancer cells, but fixing what’s driving disease in the first place.”
Beyond Healthcare: Global Impact
With 75% of emerging infectious diseases originating in animals, Chris believes prevention at the source is essential not only for public health but for economies and societies worldwide. COVID-19, he points out, was a stark reminder of the trillions lost when zoonotic diseases reach humans.
“If we don’t address diseases where they start—in animals—we’re going to keep repeating the same cycles,” he warns.
Patient Experience Matters
One of Lloyd’s biggest concerns is quality of life. Today, he argues, the patient experience ranks far too low in cancer care. Endurex’s vision is to change that—making treatments not only more effective but also less devastating physically and emotionally.
“Improved outcomes aren’t just about survival,” he emphasizes. “They’re about how you live during and after treatment.”
Looking Ahead
Endurex remains early-stage, supported largely by grants and founder investment. But Lloyd is energized by the possibilities. “We’re building a delivery platform with a wide field of use,” he says. “If we succeed, we won’t just improve cancer treatment—we’ll transform how medicine thinks about precision, process, and people.”
Listen to the full episode.
Interested in being featured on the podcast? Reach out to podcast@industryignited.com
